Change of prognosis of patients with myelodysplastic syndromes during the last 30 years

A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: The Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry

“…The OS curve (Figure 1A) is similar to other large analysis,1,6 although different study cohorts are not comparable, as observed in the recent report of Della Porta et al,27 mainly due to different proportion of high risk patients and variable median age. The Kaplan-Meier curve stratified by MDS subtype according to 2008 WHO classification (Figure 1B), is similar to other studies of the same type,28 with shorter survival for patients with RAEB I or RAEB II.…”

“…However, in individuals aged over 70 years, the incidence constantly increases up to 40–60 /100,000 2,3. Survival of MDS patients is poor,4 with 2–4 years reported median overall survival (OS) 1,5,6. Factors known to impact survival include age, the number of blasts, cytogenetic profile, cytopenias, transfusion requirements and disease type, according to 2008 WHO classification 7.…”

“…In the last decades, in several countries, many registries have been created as the “Surveillance and epidemiological and End Results” (SEER) from the National cancer Institute,5 the “Dusseldorf registry” started in 1986,6 the “Netherlands Cancer Registry”, established in 19892,13 or the “Victorian Cancer Registry”,14 which provided a basis for epidemiological and clinical studies in MDS.…”

Myelodysplastic Syndromes in Pakistani Population-Analysis of 52 Cases and their Outcome on Best Available Treatment Options

“…The survival and rate of leukemic progression of 4147 patients from the Duesseldorf MDS registry diagnosed during the last 30 years and found an improvement of survival in those patients diagnosed after 2002 (30 vs. 23 months, p<0.0001). In detail, the improvement of the prognosis was restricted to high-risk MDS patients diagnosed between 2002 and 2014 in comparison to the patient group diagnosed between 1982 and 2001 (19 vs 13 months, p<0.001), whereas the prognosis of low-risk MDS patients did not change significantly [6].…”

“…With recent therapeutic advancements and provision of best supportive care better outcome of MDS is seen in published data from developed countries [6]. The majority of de novo MDS patients are diagnosed with lower or intermediate risk disease, and although prognosis in this ample subgroup of patients is highly heterogeneous, their most frequent problem is, at least in two-thirds of the cases, confined to anemia.…”